Trial
NCT01068756
Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
AstraZeneca
Collaborators
Bristol-Myers Squibb
Condition
Type 2 Diabetes Mellitus
Intervention
Dapagliflozin
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-10-17